Drug discovery research for clinical application of PCA-1 inhibitors

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08036
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Drug development chemistry
• Research Institution: Hyogo University of Health Sciences
• Principal Investigator: TOKORO(MABUCHI) Miyuki (馬渕美雪) 兵庫医療大学, 薬学部, 研究員 (60714897)
• Co-Investigator(Kenkyū-buntansha): 辻川 和丈 大阪大学, 薬学研究科, 教授 (10207376) ; 田中 明人 兵庫医療大学, 薬学部, 教授 (30454789)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: PCA-1 / ALKBH3 / 抗がん剤 / 前立腺がん / Docetaxel / 併用効果 / 悪性中皮腫 / MESO-4

Outline of Final Research Achievements

We previously developed a novel PCA-1 inhibitor, named HUHS015. We examine anti-cancer effects of HUHS015 in combination with known anti-cancer drugs in our continuous studies. In this study, hormone-independent prostate cancers and malignant mesothelioma were used. We found synagistic effects of HUHS015 in vitro in combination with Docetaxel and Cisplatin, which were often clinically used for hormone-independent prostate cancers treatment. We also found that combinational treatment of HUHS015 with Cisplatin, Irinotecan, Doxorubicin, Vinorelbine and Gemcitabine in malignant mesothelioma synergistically inhibited growth of malignant mesothelioma cells in vitro. Furthermore, additive effects of HUHS015 comibinatorial uses with Docetaxel in vivo were demonstrated, that is, administration of 1 and 2.5 mg/kg of Docetaxel with 32 mg/kg of HUHS015 were more potent than that of only Docetaxel administrations.

Free Research Field

薬理